TSE:APS Aptose Biosciences - APS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. C$1.05 +0.04 (+3.96%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's RangeC$0.97▼C$1.0550-Day RangeC$0.60▼C$1.0552-Week RangeC$0.60▼C$1.92Volume63,138 shsAverage Volume19,339 shsMarket CapitalizationC$96.91 millionP/E RatioN/ADividend YieldN/APrice TargetC$8.50 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesHeadlinesSocial Media About Aptose Biosciences (TSE:APS) StockAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Read More Receive APS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address APS Stock News HeadlinesDecember 30, 2022 | finance.yahoo.comWe Think Aptose Biosciences (TSE:APS) Needs To Drive Business Growth CarefullyDecember 12, 2022 | ca.finance.yahoo.comStocks in play: Aptose Biosciences IncFebruary 5, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...September 27, 2022 | finance.yahoo.comSeagen (SGEN) Inks Deal With LAVA Therapeutics for LAVA-1223September 13, 2022 | finance.yahoo.comAptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D.September 12, 2022 | benzinga.comAptose's New "G3" Formulation of Luxeptinib Boosts BioavailabilityJuly 23, 2022 | finance.yahoo.comIs Aptose Biosciences (TSE:APS) In A Good Position To Invest In Growth?July 19, 2022 | finance.yahoo.comAptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022February 5, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...May 9, 2022 | finance.yahoo.comAptose Reports Results for the First Quarter 2022May 4, 2022 | finance.yahoo.comAptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 MutationMarch 8, 2022 | finance.yahoo.comAptose to Report Fourth Quarter and Full Year 2021 Financial Results and Hold Conference Call on Tuesday, March 22, 2022March 1, 2022 | finance.yahoo.comAptose to Present at Oppenheimer’s 32nd Annual Healthcare ConferenceDecember 16, 2021 | msn.comAptose Biosciences Climbs 17% to Reclaim Some LossesDecember 15, 2021 | finance.yahoo.comInsiders who purchased this year lose US$89k as Aptose Biosciences Inc. (TSE:APS) stock drops to CA$1.44December 13, 2021 | finance.yahoo.comHM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid LeukemiaNovember 26, 2021 | finance.yahoo.comImplied Volatility Surging for Aptose Biosciences (APTO) Stock OptionsNovember 24, 2021 | finance.yahoo.comWhy Investors Should Hold on to Universal Health (UHS) StockNovember 22, 2021 | finance.yahoo.comAptose to Present at the Piper Sandler 33rd Annual Healthcare ConferenceNovember 11, 2021 | finance.yahoo.comAptose Reports Results for the Third Quarter 2021November 4, 2021 | finance.yahoo.comAptose Clinical Data to be Presented at the 2021 ASH Annual MeetingAugust 19, 2021 | finance.yahoo.comAzurRx (AZRX) Pancreatic Insufficiency Study Meets EndpointsAugust 18, 2021 | finance.yahoo.comAgios (AGIO) Rare Disease Drug NDA Gets FDA Priority ReviewAugust 6, 2021 | finance.yahoo.comAptose Biosciences (APTO) Loses 19.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerAugust 3, 2021 | finance.yahoo.comAptose Reports Results for the Second Quarter 2021August 2, 2021 | finance.yahoo.comWe Think Aptose Biosciences (TSE:APS) Can Afford To Drive Business GrowthJuly 26, 2021 | finance.yahoo.comWere Hedge Funds Right About Cutera, Inc. (CUTR)?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive APS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address APS Company Calendar Today2/05/2023Next Earnings (Estimated)3/28/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolTSE:APS CUSIPN/A CIKN/A Webaptose.com Phone+1-647-4799828FaxN/AEmployees31Year FoundedN/APrice Target and Rating Average Stock Price ForecastC$8.50 High Stock Price ForecastC$12.00 Low Stock Price ForecastC$5.00 Forecasted Upside/Downside+709.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.58 Current Ratio5.53 Quick Ratio5.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.66 per share Price / Cash Flow1.60 Book ValueC$0.51 per share Price / Book2.07Miscellaneous Outstanding Shares92,295,000Free FloatN/AMarket CapC$96.91 million OptionableNot Optionable BetaN/A Key ExecutivesDr. William G. Rice Ph.D. (Age 59)Chairman, Pres & CEO Mr. Gregory K. Chow CPA (Age 45)MBA, BA, Sr. VP, CFO & Principal Accounting Officer Mr. Ernest Kitt B.S.M.S, VP of Devel. & Technical OperationsDr. Stephen B. Howell (Age 73)Chief Medical Officer Mr. Peter MurrayDirector of Clinical Devel.Key CompetitorsIntelGenx TechnologiesCVE:IGXNovoheartCVE:NVH138267 (COM.TO)TSE:COMScythian BiosciencesCVE:SCYBMedicenna TherapeuticsTSE:MDNAView All CompetitorsInsiders & InstitutionsWilliam Glenn RiceBought 5,700 shares on 9/19/2022Total: C$5,025.04 ($0.88/share)William Glenn RiceBought 2,776 shares on 6/6/2022Total: C$3,375.69 ($1.22/share)View All Insider Transactions APS Stock - Frequently Asked Questions Should I buy or sell Aptose Biosciences stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" APS shares. View APS analyst ratings or view top-rated stocks. What is Aptose Biosciences' stock price forecast for 2023? 3 brokers have issued 12 month target prices for Aptose Biosciences' shares. Their APS share price forecasts range from C$5.00 to C$12.00. On average, they anticipate the company's stock price to reach C$8.50 in the next year. This suggests a possible upside of 709.5% from the stock's current price. View analysts price targets for APS or view top-rated stocks among Wall Street analysts. How have APS shares performed in 2023? Aptose Biosciences' stock was trading at C$0.78 at the beginning of the year. Since then, APS shares have increased by 34.6% and is now trading at C$1.05. View the best growth stocks for 2023 here. When is Aptose Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023. View our APS earnings forecast. What other stocks do shareholders of Aptose Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aptose Biosciences (APTO), Aurinia Pharmaceuticals (AUPH), Advanced Micro Devices (AMD), NVIDIA (NVDA), Aurora Cannabis (ACB), Adobe (ADBE), AltaGas (ALA), Aphria (APHA), Algonquin Power & Utilities (AQN) and Badger Daylighting (BAD). What is Aptose Biosciences' stock symbol? Aptose Biosciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "APS." How do I buy shares of Aptose Biosciences? Shares of APS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What is Aptose Biosciences' stock price today? One share of APS stock can currently be purchased for approximately C$1.05. How much money does Aptose Biosciences make? Aptose Biosciences (TSE:APS) has a market capitalization of C$96.91 million. How can I contact Aptose Biosciences? Aptose Biosciences' mailing address is 5955 Airport Rd Suite 228, MISSISSAUGA, ON L4V 1R9, Canada. The official website for the company is aptose.com. The biotechnology company can be reached via phone at +1-647-4799828. This page (TSE:APS) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.